Dr. Liu has been interested in developing nanomaterial-based platforms for early detection of pancreatic cancer. His group is involved in developing fast, sensitive, and cost-effective lateral-flow devices for detection of protein and micro-RNA biomarkers present in bodily fluids of pancreatic cancer patients.
Dr. Kim's research is focused on investigating the perivascular heterogeneity in Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment (TME). The research is aiming to identify novel mechanisms to reprogram the perivascular signature that will promote vascular functionality and enhance drug delivery efficacy. The Kim group utilize in vitro cell culture system to study mechanistic details and animal model system including various Genetically Engineered Mouse Models (GEMM), to evaluate the efficacy of new findings in vivo.
Dr. Mohi Quadir is aiming to develop spatially and temporally-responsive drug delivery nano carriers for pancreatic cancer. The Quadir group is involved in designing linear and dendritic block copolymers that forms nano-sized polymersomes and vesicles capable of encapsulating frontline chemotherapeutic agents and trafficking them to specific cellular compartments without triggering off-target toxicity.
Dr. Reindl’s research is focused on the roles of small molecule phytochemicals (e.g., piperlongumin) in inducing oxidative stress which kills K-ras oncogene harboring pancreatic cancer cells. The mechanistic details, as well as therapeutic potentials of piperlongumin in combination of gemcitabine, are being investigated at both cellular and model animal levels.